Patent ID: 8361459

Claim:
A pharmaceutical composition for treating a patient having an acute neurodegenerative condition, comprising a pharmaceutically acceptable carrier and umbilical cord tissue-derived cells in an amount effective to treat the neurodegenerative condition wherein the umbilical cord tissue-derived cells are derived from umbilical cord tissue substantially free of blood, wherein the cells are capable of self-renewal and expansion in culture and have the potential to differentiate into cells of at least a neural phenotype; wherein the cells require L-valine for growth and can grow in at least about 5% oxygen; wherein the cells do not produce CD117; and wherein the cells further comprise at least one of the following characteristics: a) potential for at least 40 doublings in culture; b) production of at least one of tissue factor, vimentin, and alpha-smooth muscle actin; c) production of at least one of CD10, CD13, CD44, CD73, CD90, PDGFr-alpha, PD-L2 and HLA-A,B,C; d) lack of production of at least one of CD31, CD34, CD45, CD80, CD86, CD141, CD178, B7-H2, HLA-G, and HLA-DR,DP,DQ; e) secretion of at least one of MCP-1, IL-6, IL-8, GCP-2, HGF, KGF, FGF, HB-EGF, BDNF, TPO, MIP1b, I309, MDC, RANTES, and TIMP1; and f) lack of secretion of at least one of TGF-beta2, ANG2, PDGFbb, MIP1a, and VEGF, as detected by ELISA.